List of Generics Companies in France - 3

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies. « Patients are central to our approaches » Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.

Theravia is an international pharmaceutical laboratory based in France, focusing on rare, neglected, and debilitating diseases. Formed from the merger of Addmedica and CTRS, the company operates in over 35 countries across five continents. Theravia is dedicated to addressing unmet medical needs through innovative therapies and strategic partnerships. The company develops, registers, and promotes specialized medical products, including pharmaceuticals, medical devices, and diagnostics. Their portfolio features six registered products, such as Siklos for sickle cell disease and Orphacol for genetic disorders affecting bile acid production. Theravia collaborates with research groups and healthcare institutions to enhance disease awareness and improve treatment accessibility for over 15,000 patients globally. With more than 20 years of experience in rare disease therapeutics, Theravia emphasizes patient-centric solutions and adaptive strategies. The company has established over 30 partnerships worldwide, reflecting its commitment to advancing healthcare for those with rare metabolic, hematologic, and immunologic conditions.